INVO Fertility, Inc. reported a revenue of $6.8 million for the fiscal year ending December 31, 2025, a 5% increase from $6.5 million in the previous year. The revenue primarily stemmed from clinic operations, with $6.7 million attributed to clinical services. However, the company also faced significant challenges, including a net loss of $25.1 million, which included a loss of $16.5 million from discontinued operations related to the divestiture of NAYA Therapeutics. This marked a substantial increase in losses compared to the previous year's net loss of $9.5 million.
The company underwent significant strategic changes during the fiscal year, including the acquisition of the Wisconsin Fertility Institute in August 2023, which more than tripled its annual revenue and transformed its business model from a medical device company to a healthcare services provider. In February 2026, INVO completed the acquisition of Family Beginnings, a fertility clinic in Indiana, for approximately $760,000. This acquisition is expected to further enhance the company's clinical footprint and support its growth strategy in the fertility services market.
Operationally, INVO Fertility has expanded its clinic network to four locations in the United States and has engaged in joint ventures to establish INVO Centers in Birmingham, Alabama, and Atlanta, Georgia. The company reported an increase in patient engagement and utilization of its proprietary INVOcell device, which allows for in vivo fertilization and early embryo development. As of December 31, 2025, INVO employed 14 full-time staff, with an additional 26 full-time and 2 part-time employees across its clinics.
The company has faced liquidity challenges, with negative working capital of approximately $7.4 million as of December 31, 2025, an improvement from $12.2 million the previous year. INVO has relied on raising capital through various financing activities, including a public offering in January 2025 that raised approximately $9.5 million and a private placement in December 2025 that generated around $4 million. Looking ahead, INVO Fertility aims to continue expanding its clinic operations and pursue additional acquisitions to achieve profitability, although it acknowledges the need for further capital to support its growth initiatives. The company has expressed concerns about its ability to continue as a going concern if it cannot secure additional funding.
About INVO Fertility, Inc.
INVO Fertility, Inc. is a healthcare services company specializing in assisted reproductive technology (ART). It operates fertility clinics, including INVO Centers utilizing its proprietary INVOcell device for in vivo fertilization, and acquires existing IVF clinics. The company focuses on expanding access to affordable fertility treatments, leveraging innovative devices and clinic networks to serve a large, underserved global market.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.